TOKYO and PALO ALTO, Calif.

东京和加利福尼亚州帕洛阿尔托

,

，

May 26, 2026

2026年5月26日

/PRNewswire/ -- bitBiome, a pioneering force in the field of discovery, design and engineering of novel enzymes, proteins, strains, and ingredients, today announced that it has closed an oversubscribed seed extension round. This investment underscores bitBiome's traction and global relevance in the engineering biology and bio-manufacturing landscape..

/PRNewswire/ -- 作为新型酶、蛋白质、菌株和成分的发现、设计与工程领域的先锋力量，bitBiome今天宣布已完成超额认购的种子扩展轮融资。这项投资突显了bitBiome在工程生物学和生物制造领域的吸引力和全球重要性。

With this investment, bitBiome is poised to accelerate its mission to discover and engineer microbial enzymes and pathways at scale, leveraging its deeply curated and fast-expanding microbial database, cutting-edge modeling and predictive capabilities, and high-throughput enzyme, pathway and strain engineering platforms.

通过这项投资，bitBiome 准备加速其大规模发现和设计微生物酶与代谢途径的使命，利用其深度策划且快速扩展的微生物数据库、尖端建模与预测能力，以及高通量酶、代谢途径和菌株工程平台。

The collaboration aligns with their partners' strategic focus on engineered biology and the bioeconomy, as a frontier technology with both commercial and strategic implications. .

该合作与其合作伙伴在工程生物学和生物经济方面的战略重点相一致，是一项具有商业和战略意义的前沿技术。

'This investment reflects our conviction that bitBiome's unique microbial database-and-model stack is a differentiator in the enzyme and strain engineering space,' said Yuji Suzuki, CEO of bitBiome. 'With this added strategic support, bringing our total equity and non-dilutive funding including grant to over 45 million USD, we will deepen our modelling-first approach to provide much higher probabilities of success, continue to expand our global presence, and drive partnerships across industrial biotech, pharma and life science, synthetic biology and advanced biomanufacturing.'.

“这项投资反映了我们对bitBiome独特的微生物数据库和模型堆栈在酶和菌株工程领域的差异化优势的信心，”bitBiome首席执行官铃木裕治表示。“通过此次增加的战略支持，我们的总股权和非稀释性融资（包括拨款）已超过4500万美元。我们将深化以建模为先导的方法，以提供更高的成功概率，继续扩大我们的全球影响力，并推动在工业生物技术、制药和生命科学、合成生物学以及先进生物制造领域的合作伙伴关系。”

As biology becomes increasingly data-driven, investors are placing greater emphasis on platforms with differentiated datasets, predictive modeling capabilities, and scalable commercialization pathways. bitBiome's integrated approach—combining microbial biodiversity, AI, and high-throughput engineering—positions the company at the forefront of this shift..

随着生物学变得越来越数据驱动，投资者更加重视拥有差异化数据集、预测建模能力以及可扩展商业化路径的平台。bitBiome通过结合微生物多样性、人工智能和高通量工程的综合方法，使公司站在了这一转变的前沿。

'We are thrilled to partner with bitBiome. The company has amassed a uniquely diverse microbial database, which combined with its advanced modeling capabilities, gives them an edge in enzyme discovery, engineering, and biomanufacturing,' said Olivia Jones, Managing Director, IQT. 'We believe this capability is strategically important, not only for commercial enzyme innovation, but also for advancing the frontier of engineered biology and biosecurity.

“我们很高兴与bitBiome合作。该公司积累了独特多样的微生物数据库，结合其先进的建模能力，使他们在酶的发现、工程设计和生物制造方面具有优势，”IQT董事总经理Olivia Jones表示，“我们认为这一能力不仅对商业酶创新具有战略重要性，同时对推动工程生物学和生物安全的前沿发展也至关重要。”

We're excited to see bitBiome scale globally.'.

我们很高兴看到 bitBiome 在全球范围内扩展。

Shinya Kasuga, General partner of IT-Farm said, 'IT-Farm is proud to make our follow-on investment in bitBiome, a leading applied AI company in data-driven bioscience, leveraging the world's largest proprietary microbial genome database to drive novel enzyme discovery for biosynthesis applications. We are particularly excited by the company's pioneering approach to scalable genome AI commercialization, built upon its unprecedented mass of data and unique strengths in microfluidics & biosynthesis technologies.

IT-Farm的普通合伙人春日伸也表示：“IT-Farm很自豪能够继续投资于bitBiome，这是一家在数据驱动的生命科学领域领先的AI应用公司，利用世界上最大的专有微生物基因组数据库，推动用于生物合成应用的新酶发现。我们对公司基于前所未有的海量数据以及在微流体和生物合成技术方面的独特优势所建立的可扩展基因组AI商业化的开创性方法感到特别兴奋。”

As a Tokyo-based cross-border deeptech VC since 1999, we look forward to further supporting the company's global fundraising and business development by leveraging our international network and decades of experience.'.

自1999年以来，作为一家总部位于东京的跨境深科技风险投资公司，我们期待通过利用我们的国际网络和数十年的经验，进一步支持公司的全球融资和业务发展。

'We are excited to partner with bitBiome as it builds a foundational data and discovery platform for the next generation of biomanufacturing,' said Andrew Hyung of Valuence Ventures. 'By combining proprietary single-cell microbial genome sequencing, one of the world's largest microbial gene databases, and AI-enabled enzyme discovery and engineering, bitBiome is unlocking microbial biodiversity that traditional approaches cannot reach and turning it into actionable commercial solutions.

“我们很高兴与bitBiome合作，因为它正在为下一代生物制造构建基础数据和发现平台，”Valuence Ventures的Andrew Hyung表示。“通过结合专有的单细胞微生物基因组测序、世界上最大的微生物基因数据库之一，以及人工智能驱动的酶发现和工程设计，bitBiome正在解锁传统方法无法触及的微生物多样性，并将其转化为可操作的商业解决方案。”

The company has paired a differentiated technology moat with real customer traction, strong capital efficiency, and a clear path toward products, data licensing, and scalable biomanufacturing applications. We are proud to support the bitBiome team as they expand globally and help establish microbial biodiversity as a new infrastructure layer for the bioeconomy.'.

这家公司将其差异化的技术护城河与真实的客户吸引力、强劲的资本效率以及在产品、数据许可和可扩展的生物制造应用方面的清晰路径相结合。我们为支持 bitBiome 团队的全球扩展感到自豪，他们正在帮助将微生物多样性确立为生物经济的新基础设施层。

'We at Darwin highly value the unique and globally rare technological foundation bitBiome has built in the field of synthetic biology. A major competitive advantage is the company's ability, through its proprietary technology platforms—'bit-MAP,' 'bit-GEM,' and 'bit-EVO'—to conduct end-to-end exploration, analysis, and implementation—from the discovery of useful genes to the development of enzymes and microbial production strains—with high precision and speed, utilizing the vast, untapped resources of microorganisms.

“在达尔文，我们高度重视bitBiome在合成生物学领域构建的独特且全球罕见的技术基础。该公司的一大竞争优势在于，通过其专有的技术平台——‘bit-MAP’、‘bit-GEM’和‘bit-EVO’，能够以高精度和高速度进行端到端的探索、分析和实施——从有用基因的发现到酶和微生物生产菌株的开发——充分利用了微生物这一庞大而未被开发的资源。

We highly appreciate the progress of their multiple product development pipelines using synthetic biology, while anticipating future customer demand. We are pleased to be able to continuously support the company's growth through this investment,' said Kazuaki Konno, Partner of Darwin Ventures..

“我们高度赞赏他们利用合成生物学在多产品开发管道方面取得的进展，同时也期待未来客户的需求。我们很高兴能够通过这项投资持续支持公司的成长，”达尔文风险投资公司的合伙人小野一昭表示。

About bitBiome

关于bitBiome

bitBiome is a biotechnology company unlocking the full potential of our planet's microbes to power the future of the bioeconomy. bitBiome's platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP

bitBiome是一家生物技术公司，致力于充分释放地球微生物的潜力，推动生物经济的未来发展。bitBiome的平台基于其专有的单细胞微生物基因组分析技术bit-MAP。

®

®

, which has enabled the creation of bit-GEM: an extensive and groundbreakingly diverse and growing microbial database of over 3 billion sequences, sourced primarily from environmental samples and predominantly containing sequences not present in public databases. Leveraging their expertise in bioinformatics, machine learning and unique use of AI technologies, the company practices a comprehensive and differentiated enzyme discovery and enzyme, pathway and diversified strain engineering platform, bit-EVO, to rapidly develop and manufacture bio-based products.

，这一技术使得bit-GEM的创建成为可能：这是一个庞大且突破性多样化、不断增长的微生物数据库，包含超过30亿条序列，主要来源于环境样本，且大部分序列在公共数据库中并不存在。凭借其在生物信息学、机器学习以及AI技术独特应用方面的专业知识，该公司构建了一个全面且差异化的酶发现与酶、通路及多样化菌株工程平台——bit-EVO，以快速开发和生产基于生物的产品。

bitBiome is committed to improving existing biomanufacturing industries and creating new ones by delivering unique nature-inspired bio-based products that cannot be enabled elsewhere..

bitBiome致力于通过提供独特的、受自然启发的生物基产品来改进现有的生物制造产业并创造新的产业，这些产品在其他地方无法实现。

To learn more about bitBiome's platform and services, visit

要了解有关 bitBiome 平台和服务的更多信息，请访问

www.bitbiome.bio

www.bitbiome.bio

.

。

Contact:

联系人：

[email protected]

电子邮件地址

SOURCE bitBiome

来源 bitBiome

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示